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CHAPTER ONE
OVERALL HYPOTHESIS AND EXPERIMENTAL GOALS
Inflammation is common to the pathogenesis of a variety of diseases. Persistent
or excessive inflammation can lead to tissue damage and promote disease in the
affected tissue. Therapeutics which can regulate and reduce damaging inflammation
and subsequent disease development are therefore valuable in the treatment of
inflammation and inflammatory diseases1.
One commonly used analgesic which has recently been identified as limiting
inflammation is lidocaine, a known numbing agent that acts by inhibiting sodium ion
channels2. Additionally, alternative, less toxic therapeutics like snake venom peptides,
Zep 3 and 4, are thought to have anti-inflammatory effects3. Recent studies have shown
that lidocaine can attenuate proinflammatory cytokine gene expression and subsequent
release from microglial cells, the resident macrophages in the central nervous system4–
14.

Snake venom peptides have also been shown to reduce cytokine release from

activated macrophages in part due to reduced gene expression15–17. Yet a well-defined
mechanism or cellular target for lidocaine or Zep peptides’ anti-inflammatory effects has
not been proposed.
The inflammatory response is mediated by the release of cytokines following the
activation of macrophages or microglial cells. Expression and release of a
proinflammatory cytokine like IL-1β requires two signals. The first priming signal
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activates the toll-like receptor 4 (TLR4) signaling pathway, and the second signal leads
to the formation of the inflammasome complex. TLR4 is activated by pathogenassociated molecular patterns (PAMPS) such as lipopolysaccharide (LPS) or damageassociated molecular patterns (DAMPS) which result in a cascade of signaling through
the myeloid differentiation primary response protein 88 (MyD88)-dependent
pathway18,19. This activation leads to the translocation of the transcription factor, nuclear
factor kappa B (NF-κB), into the nucleus resulting in the upregulation of the gene
expression of proinflammatory cytokines such as IL-6 and proIL-1β18,19. A second signal
such as ATP initiates the assembly of the NLR family pyrin domain containing 3
(NLRP3) inflammasome complex that activates the protease, caspase-1. Caspase-1
then cleaves proIL-1β into its mature form allowing it to be secreted from the cell. This
cytokine and others can then recruit other immune cells causing inflammation 18.
The canonical inflammatory pathway does not indicate a regulatory role for
sodium ion channels. More broadly, lidocaine is known to non-selectively inhibit cation
channels3,7. In this context, lidocaine may inhibit ion channels to affect inflammatory
signaling, reducing the release of IL-1β and other cytokines. For example, ATPactivated microglial cells have elevated levels of intracellular Ca2+ corresponding to
increased cytokine release14,19. Lidocaine treatment of the ATP-activated microglial cells
significantly reduced intracellular Ca2+ concentrations14. Perhaps lidocaine attenuates
the inflammatory response by inhibiting an ion channel to minimize activation.
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Another related pathway, the mitogen-activated protein kinase (MAPK) pathway,
responds to stress stimuli to regulate gene expression. These signals include
fluctuations in intracellular cation concentrations. For example, diminished intracellular
[Ca2+] signal the MAPK pathway to minimize the response to proinflammatory signals by
downregulating cytokine gene transcription14,18. Furthermore, NF-κB can also be
activated by stress stimuli, so both MAPK signaling and NF-κB activation may contribute
to reduced cytokine secretion19.
Similarly, snake venom peptides have also been shown to have antiinflammatory effects15,16. Like lidocaine, they are classically recognized for their
analgesic properties15,16. For example, the Neurotoxin-Nna from the venom of Naja naja
atra has been found to attenuate IL-1β release and inhibit activation of NF-κB15,16. While
not much is known about Zep peptides specifically, they may have anti-inflammatory
effects comparable to Neurotoxin-Nna and lidocaine. The goal of this project is to
understand how lidocaine and Zep peptides act as anti-inflammatory agents on
activated macrophages.
Since lidocaine and snake venom peptides have been shown to have antiinflammatory effects on inflammatory models through reduced proinflammatory
cytokine secretion, we hypothesize that lidocaine and Zep peptides also are able
to exert these effects on macrophages by (1) interacting with a cellular target to
decrease intracellular cation concentrations and by (2) downregulating MAPK and
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NF-κB signaling pathways to reduce proinflammatory cytokine expression and
release.
Our first aim was to define how lidocaine attenuates proinflammatory cytokine
release from macrophages. We hypothesized that lidocaine interacts with an ion
channel to inhibit the MAPK and NF-κB signaling pathways to reduce proinflammatory
cytokine release from activated macrophages. The goal was to understand the
mechanism of how lidocaine reduces macrophage activation. Based on the literature,
we believed that lidocaine interacts with the cell to inhibit the MAPK and NF-κB
signaling pathways, reducing gene expression of the cytokines IL-1β and IL-64,5,7–13.
Less gene expression would result in diminished cytokine secretion. The experiments
described in Chapter 4 were aimed at determining the mechanism of how lidocaine
attenuates macrophage activation and subsequent cytokine secretion.
Our second aim was to determine if Zep peptides exert an anti-inflammatory
effect on activated macrophages. We hypothesized that Zep peptides interact with a
cellular target to inhibit NF-κB activation, decreasing proinflammatory cytokine release.
The goal was to assess how Zep peptides reduce macrophage activation to attenuate
the release of inflammatory mediators. Recent literature suggested that snake venom
peptides exert an anti-inflammatory effect by decreasing NF-κB activation15–17. The
experiments outlined in Chapter 5 were targeted towards determining if Zep peptides
reduce macrophage activation by downregulating proinflammatory cytokine gene
expression to decrease cytokine release.
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Chapter 2 will consist of a review of the literature. It will provide an outline of the
role of inflammation in disease and the disadvantages and advantages of current
therapeutics to highlight the need for a better understanding of inflammatory pathways.
The canonical inflammatory pathway will be detailed with special emphasis on activation
of TLR4 signaling and NLRP3 inflammasome formation. Then lidocaine’s analgesic
mechanism will be outlined followed by an introduction to the role ion channels play in
inflammation. It will be followed by a review of local anesthetics and inflammation with a
focus on lidocaine and snake venom peptides’ activity as an anti-inflammatory. Finally,
a role for sodium, calcium, and potassium channels in regulation inflammation will be
described.

CHAPTER TWO
REVIEW OF THE LITERATURE
Inflammation and Disease
Acute and Chronic Inflammation.
Inflammation is a host defense mechanism of protection against infection or
injury. The goal of this defense is preventing the spread of a pathogen followed by its
eradication and subsequent wound healing. First identified around 40 AD by Celsus, the
cardinal signs of inflammation include swelling, heat, pain, and redness20,21. The
inflammatory response is mediated by small proteins called cytokines. The IL-1 family
cytokines are known to cause fever22.
Typically, acute inflammation resolves once the initial signal that triggered the
response is cleared. However, when the signal persists, chronic inflammation is
induced. Some signals that trigger chronic inflammatory responses include chronic
infection, unrepaired tissue damage, persistent allergens, and indigestible crystals
among others23. Chronic inflammation is increasingly a common cause of disease in
industrialized countries. It is a risk factor that contributes to the cause or complications
associated with obesity, type 2 diabetes, arthritis, cancer, and neurodegenerative
diseases23–25. In some cases, the inflammatory response may be causing more damage
than the initial cause of infection or signal that triggered the inflammatory response21.
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There are many challenges associated with trying to develop drug therapies that
aim to reduce the inflammatory response. New drug therapies need high specificity and
high affinity for the target ligand, low toxicity, and high biostability23. None of these ideal
characteristics are easy to address within the context of inflammation and inflammatory
diseases. However, they are essential to the development of both safe and effective
drug therapies. The crux of the problem is that the immune response needs to be tightly
regulated to ensure that the response is appropriate. Where to draw the line between an
appropriate and an excessive response is exceedingly difficult.
Surgery-Induced Inflammation.
Not all inflammation is induced in response to an invading pathogen as shown in
Figure 1. In the absence of an infection, the response is known as sterile inflammation.
One example is surgery-induced inflammation. Prior to surgery, local anesthetics are
usually applied topically or injected into the surgical site26. Surgery itself induces a local
inflammatory response at the site of tissue injury. Local anesthetics like lidocaine have
been shown to reduce the release of cytokines and chemokines in the acute
inflammatory response, yet there is still slow resolution of inflammation and the return to
homeostasis26. Within the context of surgery, local anesthetics may have an added
benefit; first, they relieve pain at the site of surgery, and later, they may attenuate the
induced inflammatory response.
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Figure 1. Causes of Inflammation and Their Pathological Consequences. The three
inflammatory triggers (infection, tissue injury, and tissue stress and malfunction) induce
inflammation resulting in a response with potentially pathological consequences.
Infection is the only activator of inflammation that induces an immune response27.
Treating Inflammatory Diseases
Currently, many of the therapies that treat inflammatory diseases aim to minimize
the symptoms, but they do not prevent progression of the disease 28. One drawback of
these therapies is that there are typically severe side effects with long-term use28. To
address these disadvantages, a more comprehensive understanding of inflammatory
pathways is imperative. This approach will fine-tune treatment to minimize side effects
and directly resolve inflammation.
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Protein Anti-Cytokine Drugs.
At present, most of the drugs that reduce the production of cytokines are
proteins29. There are many drawbacks to using protein drugs to treat inflammatory
diseases29. These drugs have poor stability, poor cellular penetration and cellular
activity, have short-half lives, are rapidly metabolized, and are expensive to produce29.
Therefore, it is increasingly important to identify new drugs that have less
disadvantages to better treat the wide range of inflammatory diseases.
Small Molecule Anti-Cytokine Drugs.
Newer therapies that are being identified or developed to target inflammatory
pathways are small molecules. These drugs tend to be orally active and are successful
at targeting proinflammatory signaling pathways in the cell to attenuate the release of
proinflammatory cytokines without the disadvantages of protein agents29. These small,
organic molecule therapeutics are likely the most appropriate type to focus on to treat
inflammatory diseases.
Canonical Inflammatory Pathway
The canonical inflammatory pathway consists of TLR4 signaling activation and
formation of the NLRP3 inflammasome as shown in Figure 2. Innate immune cells such
as macrophages respond to infection or tissue injury by releasing proinflammatory
mediators that include cytokines and chemokines to attract circulating leukocytes to the
affected tissues23. To initiate the inflammatory response in macrophages, two signals
are required. The first, priming signal activates TLR4, a transmembrane protein in the
plasma membrane that responds to extracellular signals to upregulate proinflammatory
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cytokine gene expression30. The second signal leads to NLRP3 inflammasome
formation allowing for the cytokine, proIL-1β, to be cleaved into its mature form30.
Cytokines are then released from the macrophage acting as the inflammatory
mediators that bridge innate and adaptive immunity. The most common cytokines
associated with the inflammatory response are TNF, IL-1, IL-6, IL-8, and IL-1023.
Cytokines such as IL-1β and IL-18 are unique because they don’t use the classic route
of secretion through the endoplasmic reticulum-Golgi; instead, their immature,
biologically inactive form that lacks a signal peptide needs to be cleaved for it to be
released from the cell30,31. Overall, cytokines elicit the inflammatory response as well as
contribute to the immune response, cell growth, and cell migration 23. These small
molecules facilitate various cellular functions by binding to a cellular receptor to initiate
downstream signaling cascades23.
The first, priming signal is commonly a specific structural feature of a bacterium
or virus classified as an extracellular pathogen-associated molecular patterns (PAMPs)
or endogenous stress signals called danger-associated molecular patterns (DAMPs)
23,24,30,32.

These signals interact with pathogen recognition receptors (PRRs) that include

the Toll-like receptors to activate a signaling cascade23,24,30,32. One common ligand for
TLR4 is lipopolysaccharide (LPS), which is found on the surface of gram-negative
bacteria. LPS treatment activates NF-κB to upregulate gene expression of NLRP3
components and pro-IL-1β33.
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Figure 2. Canonical Inflammatory Pathway. Two signals are required for upregulation
and release of proinflammatory cytokines. The first priming signal (LPS binding to
TLR4) upregulates gene expression of IL-1β and NLRP3. The priming signal
deubiquitinates NLRP3 and linearly ubiquitinates and phosphorylates the adaptor
protein ASC to initiate inflammasome assembly. A second signal is then required to
activate the NLRP3 inflammasome. The four common stimuli for NLRP3 activation
include relocalization of NLRP3 to the mitochondria, mitochondrial release of ROS,
mtDNA, and cardiolipin, potassium efflux through the P2X7 receptor, or lysosomal
destabilization leading to the release of cathepsin. The active NLRP3 inflammasome
allows caspase-1 to cleave proIL-1β and proIL-18 into their mature forms that can then
be secreted and mediate the inflammatory response24.
Upregulation of proinflammatory cytokine gene expression is dependent upon
NF-κB activation through its canonical pathway. More generally, NF-κB is the
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transcription factor that mediates upregulation of proinflammatory cytokine gene
expression upon infection or injury, but it also plays a key role in resolution of the
inflammatory response by upregulating anti-inflammatory genes and genes governing
apoptosis23. Specifically, the NF-κB subunits p65 and p50 are responsible for its role in
the inflammatory response23. Several kinases phosphorylate IκBα, the inhibitor of the
NF-κB subunits p65/p50 that keeps the transcription factor sequestered in the
cytoplasm23,34. Phosphorylated IκBα is then polyubiquitinated and marked for
degradation by the 26S proteasome23,34. This step allows for NF-κB to translocate into
the nucleus where it can bind to the DNA to upregulate inflammatory target genes
among others23,25,34.
A second signal is then required to initiate NLRP3 inflammasome formation. One
potential signal such as ATP is required to activate the P2X7 receptor, an ATP-gated ion
channel expressed in monocytes and macrophages35. Concentrations greater than 1
mM ATP are required for activation of the P2X7 receptor leading to NLRP3
inflammasome activation and cleavage of proIL-1β into its mature, secreted form35. IL1β is then able to recruit other immune cells to initiate an inflammatory response.
Another cytokine of interest is IL-6. It has a unique role in recruiting neutrophils
as part of the innate immune response28. As the immune response shifts from innate to
adaptive, this cytokine initially attracts monocytes and lymphocytes then it assists in the
resolution of inflammation and tissue repair28. Release of IL-6 is not dependent on
inflammasome activation because it has a signal sequence that allows it to follow the
conventional secretory pathway28. There are nuances to the activation of NF-κB
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subunits in the case of IL-6 that are worth noting36. For example, transcription of IκBζ is
induced with LPS activation to specifically bind to the p50 subunit of NF-κB that can
then associate with the IL-6 promoter36. Therefore, the canonical inflammatory pathway
is complex, and that the diverse mechanisms that regulate these pathways still need to
be well-defined.
Toll-like Receptor 4 Signaling
TLR4 is expressed on a variety of different cell types that include macrophages,
cardiac myocytes, and cells in the CNS37. It can be activated by a variety of wellcharacterized exogenous PAMPs and endogenous DAMPs37. As shown in Figure 3, it
most classically senses LPS, requiring the interaction between TLR4 and myeloid
differentiation 2 (MD2)37. There is homodimerization of TLR4 that leads to
conformational changes that recruit the adaptor protein, myeloid differentiation primary
response protein 88 (MyD88)37. In the absence of MyD88, there is delayed activation of
NF-κB and MAPK signaling pathways suggesting that the MyD88-dependent pathway is
necessary for efficient upregulation of proinflammatory cytokine gene expression 38.
Downstream signaling through this pathway leads to activation of transforming
growth factor β-activated kinase 1 (TAK1)37,39. TAK1 then activates the mitogenactivated protein kinases (MAPKs), JUN N terminal kinase (JNK), p38, extracellular
signal-regulated kinases (ERK1/2), and the IκB kinase complex (IKK) that activate the
transcription factors, NF-κB and activator protein-1 (AP1)37,39. TLR activation results in
the upregulation of a large number of genes related to antimicrobial defense, metabolic
changes, and tissue repair in macrophages as well as both pro- and anti-inflammatory

14

genes40. The role that TLR activation plays in infections, inflammation, autoimmunity,
cancer, and allograft rejection/inflammation is still minimally understood, but it is
important to understand this pathway for the development of new therapeutics41.

Figure 3. TLR4 Signaling Pathway. Binding of LPS stimulates homodimerization of
TLR4. MyD88 is then recruited to the TIR domain of the TLR4 dimer. MyD88 recruits
the IRAKs and TRAF6 to activate TAK1. TAK1 then initiates activation of the MKKs in
the MAPK signaling pathway and IKK in the NF-κB signaling pathway. The inhibitors of
the transcription factors, AP-1 and NF-κB, are marked for degradation allowing for
translocation of the transcription factors into the nucleus. Then there is upregulation of
proinflammatory cytokine gene expression. The MyD88-independent pathway leads to
upregulation of Type 1 interferons, but that type of response is not of interest in this
study37.
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Activation of the NLRP3 Inflammasome
Mechanism of Activation.
Several PRRs such as nucleotide-binding domain, leucine-rich repeat containing
proteins (NOD-like receptors, NLRs) play a critical role in inflammasome activation by
sensing signals like DAMPs and PAMPs to upregulate NLRP3 expression and
contribute to inflammasome activation via other poorly understood mechanisms 24,42.
Part of the response to the priming signal causes deubiquitination of NLRP3 which is a
fast post-translational modification compared to the more commonly described changes
in transcription43.
A variety of disparate but generally accepted mechanisms activate the NLRP3
inflammasome. These mechanisms include potassium efflux from the cell44,
relocalization of NLRP3 to the mitochondria, mitochondrial release of ROS,
mitochondrial DNA, cadiolipin, and cathepsin release from destabilized lysosomes 24,45.
Commonly accepted signals include ATP, pore-forming toxins, crystalline substances,
nucleic acids, hyaluronan, and fungal, bacterial, and viral pathogens24,30,45. It is
hypothesized that these diverse signals converge on a point in the signaling pathway to
induce NLRP3 inflammasome activation24,45. There also is some evidence to suggest
that an increase in intracellular calcium is associated with inflammasome activation24,45.
Again, there is controversy regarding how all these signals can initiate inflammasome
formation.
Inflammasomes are typically composed of a sensor protein (NLR), an adaptor
protein (ASC), and a zymogen such as procaspase-145. Procaspase-1 is constitutively
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expressed in monocytes and macrophages, so its activity needs to be tightly regulated
by the inflammasome44,46. The NLRP3 inflammasome can be activated by whole
pathogens, environmental irritants, or cell-derived signals that indicate cellular damage
or stress46. When activated, NLRs form a scaffold that activates caspase-124. Active,
fully cleaved, caspase-1 which is a protease can then cleave interleukin-1 (IL-1)
proteins into their mature form to be secreted from the cell24,47. It also can induce
pyroptosis, a form of inflammation-associated cell death24,47. Pyroptosis occurs through
swelling of the cytoplasm and rupture of the plasma membrane30.
To ensure that there is not generally aberrant activation, there are a variety of
negative regulators in the pathway48. The canonical inflammatory pathways are
generally mediated by protein kinases and ubiquitin ligases49. Thus, it can be negatively
regulated by phosphatases and de-ubiquitin ligases49. It has recently been shown that
among various NLRP3 agonists reducing cytosolic levels of K+ is necessary and
sufficient to activate caspase-150. Furthermore, an increase in intracellular Na+
concentrations contribute to but are not required for inflammasome activation50. As
evidenced here, there are several examples of the inflammatory pathways being
activated or regulated by changes in intracellular cation concentrations.
Role in Disease.
In neurological diseases, misfolded protein aggregates and excessive
accumulation of metabolites act as endogenous DAMPs that lead to activation of the
NLRP3 inflammasome24. One type of systemic inflammation is caused by missense
mutations in NLRP3 that lead to the overproduction of inflammatory cytokines 51. It
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causes the following diseases: familial cold autoinflammatory syndrome, Muckle-Wells
syndrome, and neonatal-onset multisystem inflammatory disease51. These diseases
cause recurrent fever, rash, conjunctivitis, and arthralgia51. A better understanding of
the NLRP3 inflammasome will allow for the development of more effective treatments
for these diseases.
Lidocaine’s Classically Characterized Inhibition of Ion Channels
Voltage-Gated Sodium Channels.
Lidocaine is currently used as a local anesthetic, and it prevents ventricular
arrythmias2. Lidocaine has analgesic effects by inhibiting voltage-gated sodium
channels (VGSCs) in neurons2. It blocks Na+ from passing through the channel pore2.
Thus, it prevents membrane depolarization in neurons to keep them from firing in
response to pain stimuli1. For lidocaine to interact with a VGSC in this manner, the drug
needs to cross the cell membrane and enter the channel from the cytoplasmic side 52.
Perhaps lidocaine has the same type of interaction with VGSCs expressed in
macrophages to mediate its anti-inflammatory properties.
One study analyzed the effect of lidocaine on chemokine release from intestinal
epithelial cells7. It was hypothesized that lidocaine reduces chemokine release by
inhibiting VGSCs7. To test this hypothesis, two VGSC agonists that open these
channels were tested with lidocaine to determine whether the drug inhibits VGSCs in
this context7. This experimental condition did not affect lidocaine’s reduction in
chemokine release7. These results suggest that either lidocaine exerts anti-
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inflammatory effect through a mechanism that doesn’t involve VGSCs or that lidocaine
interacts with the channels in a different way than the two agonists that were used.
Potassium Channels.
In the literature, it has been shown that lidocaine also interacts with potassium
channels. Predominantly expressed in immune cells, P2X receptors are a class of
ligand-gated ion channels that are permeable to sodium, potassium, and calcium53.
Modeled using Xenopus oocytes, lidocaine was shown to inhibit current through ATPactivated purinergic P2X7. It was found that lidocaine noncompetitively inhibited the
P2X7 receptor as evidenced by the ATP concentration-response curve53. Additionally,
the use of two specific agonists for P2X7 were unable to block the activity of lidcaine 53.
Unique to this study, the positively-charged analog of lidocaine, QX-314, was either
injected into the oocyte or was applied extracellularly to determine whether the target of
lidocaine was localized on the plasma membrane or localized intracellularly53.
Interestingly, QX-314 applied extracellularly or intracellularly reduced ATP-induced
currents53. Thus, lidocaine may act at the plasma membrane in its charged form or it
may cross the membrane in its uncharged form to also act intracellularly53. There are
still some open questions regarding how lidocaine interacts with ion channels and the
effect these different interactions have on the cell.
Ion Channels and Inflammation
In general, ion gradients are essential to healthy cells, and ion fluxes contribute
to activation of signaling pathways and enzymes43. There is some evidence suggesting
that ion channel expression or activity contributes to inflammation in the following
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diseases: diarrheal illness, pyelonephritis, allergy, acute lung injury, and systemic
inflammatory responses such as septic shock20. The major ion channels that have been
identified in this role include sodium, chloride, calcium, potassium, transient receptor
potential, purinergic receptor, and acid-sensing ion channels20. Recently, ion channels
have become attractive drug targets because they play a critical role in a variety of
cellular functions54. Currently, approximately 15% of drugs target ion channels to
ameliorate disease54.
In the inflammatory response, when cells are activated by a second signal, ATP,
there is a change in ionic intracellular concentrations from high K+, low Na+, and low Clto low K+, high Na+, and high Cl-55. Furthermore, an increase in intracellular Na+ coupled
with a decrease in intracellular K+ is required for an unidentified step in P2X7 activation
of caspase-156–58. It has also been shown that release of IL-1β corresponds to an
increase in intracellular Ca2+ that was released from the ER in conjunction with the
required ATP-induced K+ efflux for secretion59. Thus, there are a variety of examples of
changes in ion concentrations affecting activation of the inflammatory response.
P2X7 Receptor.
P2X receptors are ion channels found on the plasma membrane that are
activated by extracellular ATP60. When ATP binds, the P2X pore switches from a closed
to open conformation that allows for ions to pass through the channel60. When ATP is
present for long periods of time, there is generation of a large pore in the plasma
membrane that allows for hydrophilic molecules of up to 900 Da to pass through the
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channel22. One study found that pharmacological inhibition of the P2X7 receptor
attenuated IL-1β release from LPS-activated spinal microglial cells61.
More recent evidence suggests that NLRP3 activation is connected to fluxes in
calcium concentration62. When there are elevated extracellular concentrations or
movement of intracellular reservoirs of calcium into the cytosol, NLRP3 is activated by
various agonists63–69. When there is a decrease in extracellular Ca2+, there is a 90%
reduction in IL-1β secretion, but this change has no effect on cleavage of proIL-1β into
its mature form by caspase-169. Specifically, the role between a decrease in intracellular
potassium concentration and an increase in intracellular calcium concentrations in
NLRP3 inflammasome activation has been controversial70. One recent study found that
an increase in intracellular [Ca2+] was not necessary or required to activate the
inflammasome in macrophages70. However, many studies were reviewed and showed
that calcium ion flux does contribute to NLRP3 activation, so it is likely that more work
needs to be done to address these discrepancies71.
Furthermore, bone-marrow derived macrophages (BMDMs) cultured with LPS,
ATP, and either extracellular Ca2+ or K+ reduced IL-1β secretion63. When LPS-only
stimulated BMDMs were cultured with Ca2+, IL-1β was secreted in an NLRP3
inflammasome dependent manner63. NRLP3 activation caused by extracellular ATP has
been shown to be affected by intracellular Ca2+ signaling65. Furthermore, LPSstimulated macrophages secreted fewer cytokines when the large-conductance Ca2+activated potassium channel MaxiK was blocked72. Blockade of this potassium channel
selectively inhibited NF-κB and MAPK p38 signaling72. Currently, there is some
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evidence in the literature showing that inhibition of ion channels has an antiinflammatory effect on cells.
Mitogen-activated protein-kinase signaling pathway.

Figure 4. Model of MAPK Signaling Pathway Regulating Ion Channel Expression.
Inflammatory mediators (IM) activate G-protein coupled receptors on the cell surface to
initiate a phosphorylation cascade of kinases. Mitogen-activated protein kinase
activated protein kinase-2 (MAPKAP kinase-2) phosphorylates to inactivate
tristetraprolin (TTP). TTP then destabilizes ion channel (IC) mRNA by binding to AU-rich
sequences. MAPKAP kinase-2 can also stabilize TTP mRNA to further contribute to
degradation of IC mRNA. MAPK can also phosphorylate and activate NF-κB to increase
IC gene expression20.
One key pathway that links VGSC and the inflammatory response is the mitogenactivated protein-kinase signaling pathway (MAPK)20. Intracellular and extracellular
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signals including peptide growth factors, cytokines, hormones, and cellular stressors are
responsible for activating MAPK signaling73. A MAP3K, apoptosis signal-regulating
kinase 1 (ASK1), is a mediator in both the p38 and JNK signaling pathways 73.
Interestingly, ASK1 is activated by several cellular stressors that include reactive
oxygen species (ROS), LPS, endoplasmic reticulum stress, and Ca2+ influx73. This
pathway is known to mediate changes in gene expression and mRNA stability of many
of the ion channels mentioned as shown in Figure 420. It is also known that p38 MAPK
signaling contributes to the transcription of TNF-α, IL-1, IL-6, and IL-828. One study
found that in LPS and ATP stimulated dorsal horn microglial cells there was widespread
phosphorylation of the p38 MAPK signaling cascade that was associated with IL-1β
release61. A second study found that by selectively inhibiting the ERK 1/2, JNK, and p38
MAPK signaling pathways, there was a reduction in IL-1β release from activated cells,
and the degree of the inhibitor’s effect on cytokine secretion depended on the activating
signal74. These results suggest that the p38 MAPK signaling pathway is contributing to
some degree to IL-1β release from activated microglia61. Additionally, when monocytes
had a 30 min pretreatment with a MAPK inhibitor before LPS activation, there was less
IL-1β protein present primarily due to less gene transcription75. Additionally, it has been
shown in the literature that there is phosphorylation in the p38 MAPK signaling pathway
resulting from activation of both TLR4 and the P2X7 receptor61. Specifically, TLR4
signaling results in phosphorylation of p38 which contributes to stabilization of the
mRNA transcripts of various cytokines61. It is likely that any anti-inflammatory drug that
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reduces the transcription of proinflammatory cytokines has some effect on the MAPK
signaling pathway.
Local Anesthetics and Inflammation
Local anesthetics are typically composed of a tertiary amine attached via an
ester or amide linkage to a substituted aromatic ring76. The classic mechanism of action
for local anesthetics is preventing Na+ from entering the cell1. This blockade prevents
membrane depolarization in neurons to prevent them from firing in response to pain
stimuli1. Local anesthetics act on Na+ channels, K+ channels, Ca2+ channels, transport
enzymes and phospholipases in excitable cells77–82. One study showed that lidocaine
had less affinity for Ca2+ channels compared to Na+ channels77. Interestingly, one study
showed that 1 mM lidocaine blocked the K+ channel TASK-2 from the tandem pore
domain K+ channels (2P K+ Channels), but the positively charged analog, QX-314 had
no effect76. The 2P K+ channels are expressed in the CNS, and they regulate the resting
membrane potential and firing of excitable cells76. The results from these studies
suggest that lidocaine can interact with a variety of channels but with different affinities.
This insight will be valuable in our investigation of how lidocaine has anti-inflammatory
effects on activated macrophages.
There are two types of anti-inflammatory drugs that are currently available26.
Classic examples act as enzyme inhibitors or receptor antagonists with more recent
drugs acting as resolution agonists26. It has been reported that local anesthetics have
anti-inflammatory properties in several contexts including reducing inflammation in
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muscle cells and cardiac tissues9. In the future, local anesthetics may be repurposed to
treat inflammatory diseases.
Lidocaine as an Anti-Inflammatory Agent
The literature suggests that local anesthetics such as lidocaine can reduce proinflammatory responses in activated microglia. In general, results from multiple studies
indicate that lidocaine pretreatment or use as a topical agent has the most antiinflammatory effects and improvement in disease models1,83–85. One study addressed
whether lidocaine can reduce inflammation associated with LPS-induced sepsis in a rat
model5. They found that there was a reduction in TLR4 and NF-κB expression and IL-6
release5. These data specifically suggest that lidocaine inhibits the TLR4 MyD88dependent signaling pathway by reducing NF-κB translocation into the nucleus5.
A few in vitro studies have analyzed how lidocaine treatment affects stimulated
cultured rat or mouse microglial cells. Several types of stimulatory molecules have been
used. In LPS-only activated cells, the data showed that lidocaine pretreatment reduced
p38 MAPK phosphorylation, NF-κB inhibitor, IκBα, phosphorylation, and NF-κB
translocation into the nucleus4. An in vitro model using RAW264.7 murine macrophages
found a decrease in IL-1β secretion and mRNA expression in LPS and lidocaine treated
cells33. In TNF-α only activated intestinal epithelial cells, there was a marked reduction
in the transcription of the inhibitor of NF-κB, IκB, decrease in the degradation of IκBα,
and a decrease in the translocation of NF-κB into the nucleus7. These results suggest
that lidocaine may be acting on a target or pathway that is upstream of the activity of the
inhibitor of NF-κB. Microglial cells stimulated with LPS and Interferon γ exhibit signs of
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cell injury6. This treatment followed by lidocaine reduced pro-inflammatory cytokine
release. Interestingly, a permanently charged analog of lidocaine exhibited a degree of
reduction of cytokine production compared to lidocaine, suggesting that lidocaine may
be interacting with the cell at the plasma membrane6. At physiological pH, lidocaine is in
both its neutral and positively charged forms, so it can cross the cell membrane or act
on the cell’s extracellular plasma membrane surface3. It is still unclear what cellular
target lidocaine has in this context.
Another study treated rat microglial cells with ATP only. ATP induces formation of
the NLRP3 inflammasome complex which allows for proIL-1β to be cleaved into its
mature form in the classical inflammatory pathway, but ATP is also known to induce
elevated intracellular concentrations of calcium14. In this study, lidocaine treated cells
had lower concentrations of ATP-induced intracellular calcium as well as decreased
levels of phosphorylated p38 MAPK and decreased mRNA and protein levels of IL-1β
and IL-614. Overall, the anti-inflammatory effect of lidocaine has been tested in several
different cell types and disease models.
Most of the data in the literature reproducibly shows that lidocaine attenuates
proinflammatory cytokine release by either downregulation or inhibition of the NF-κB
signaling pathway in activated microglia or macrophages as well as other cell types4,5,7–
13.

Concentrations of lidocaine ranging from 0.2 mM to 20 mM have been shown to

reduce the secretion of IL-1β (comparable to 50 μg/mL to 5 mg/mL)9. However, there is
some evidence to suggest that lidocaine treatment of LPS-activated macrophages also
affects inflammasome formation leading to reduced activation of caspase-133. Wen et al.

26

also showed that lidocaine reduces the occurrence of pyroptosis which is a
proinflammatory form of cell death33.
The current literature consistently demonstrates that lidocaine inhibits p38 MAPK
phosphorylation and NF-κB translocation into the nucleus and that it attenuates proinflammatory cytokine production4–6,14,86. These studies are starting to show pieces of
lidocaine’s anti-inflammatory effect, but there still needs to be more consensus in the
field and the proposal of a well-defined mechanism of action.
Snake Venom Peptides as Anti-Inflammatory Agents
Snake venoms have been used as a form of alternative anti-inflammatory
medicine in China for centuries15,87. This venom contains a diverse set of molecules that
include toxins, enzymes, and other bioactive factors that have been found to have antitumor, anti-inflammatory, anti-stroke, and analgesic effects15,87. There are several
studies in the literature that are examining whether these molecules derived from snake
venom have anti-inflammatory properties and their mechanisms of action15–17. One
study modeled pulmonary fibrosis in mice using LPS-induced inflammation15. Prior to
this study, it had been shown that naja naja atra venom (NNAV) or some component of
it had anti-inflammatory effects in a rheumatoid arthritis mouse model15. NNAV consists
of several different molecules including a neurotoxin, a cardiotoxin, nerve growth factor,
phospholipase A2, and cobra venom factor15. Thus, it is difficult to know which specific
factor is responsible for the anti-inflammatory effects. There was a significant reduction
in IL-1β and TNF-α found in the serum of animals treated with NNAV compared to
control only15. Additionally, NF-κB activation was measured. With LPS treatment, the
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p65 subunit was translocated from the cytoplasm to the nucleus, yet with NNAV
treatment there was a significant reduction in NF- κB translocation into the nucleus15. It
is worth noting that the dose of NNAV used in this study was very small compared to
the dose injected by a snake bite15. More adverse effects are seen with the dose of a
snake bite, but significantly lower therapeutic doses can potentially be beneficial with
reduced side effects15.
A second study analyzed the anti-inflammatory effects of a specific peptide
isolated from Naja naja atra venom. The peptide, neurotoxin-Nna (NT), had previously
been characterized as an analgesic that binds to the nicotinic acetylcholine receptor to
block the transmission of the nerve impulse16. This study treated with NT for 1 hr. before
inducing inflammation with carrageenan, a linear, sulfated polysaccharide found on
seaweed16. Pretreatment with NT before carrageenan attenuated IL-1β and TNF-α
release at least in part by a reduction in NF-κB activation16.
Another study found that a small peptide isolated from sea snakes has antimicrobial and anti-inflammatory properties17. They inhibit LPS-induced production of
TNF-α, IL-1β, and IL-617. It has been found that they act by either directly binding and
neutralizing LPS or by binding to the TLR4/MD2 complex to prevent homodimerization
and downstream signaling17. Furthermore, in a murine colitis model, mice were treated
with a peptide derived from Hydrophis cyanocinctus venom88. Treated mice had
reduced phosphorylation of IκB and NF-κB activation accompanied by reduced
phosphorylation of p38, JNK, and ERK1/2 in the MAPK pathway88. It was also found
that a disintegrin from the venom of Trimeresurus mucrosquamatus inhibits the release
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of proinflammatory cytokines from activated macrophages89. In treated cells, there was
decreased MAPK phosphorylation and inhibition of NF-κB activation89.
While there is little known about the Zep peptides that were used in this study,
the literature suggests some potential mechanisms of action for the anti-inflammatory
activity of characterized snake-derived peptides. Finally, recent work demonstrates that
snake venom peptides can attenuate cytokine release, but it fails to propose a specific
mechanism for their action or test the effects of peptides on more broadly relevant
models like human macrophage cell lines.
Potential Role for Sodium Channels
Voltage-Gated Sodium Channels.
As stated earlier, within the context of pain relief, lidocaine acts on VGSCs to
prevent sodium ions from passing through the channel2. Lidocaine and other VGSC
blockers prefer to interact with the ion channel in its inactive state specifically at the α
subunit52. Sodium channels are expressed in several non-excitable cell types including
macrophages to contribute to many of the cell’s common functions90,91. There are nine
different voltage-gated sodium channels (Nav1.1-Nav1.9) that share homologous
structural elements, but they each have distinct interactions with pharmacological
agents90,91. Macrophages specifically express TTX-S current, Nav1.5, and Nav1.690.
There is evidence of upregulation of the sodium channels Nav1.5 and Nav1.6 in various
disease states in microglial cells91. The use of TTX and phenytoin, toxins that
specifically bind VGSC, reduce the release of cytokines and chemokines from activated
microglial cells91. Additionally, in microglial cells treated with a combination of lidocaine
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and VGSC inhibitors then LPS, there was a reduction in activation of TLR-4, NF-κB, and
MAPK86. When exploring lidocaine’s anti-inflammatory activity on macrophages,
voltage-gated sodium channels are unlikely to first come to mind as lidocaine’s most
likely cellular target. There have been few studies that have first asked the question of
whether the same ion channels are expressed in neurons as well as macrophages and
microglia and second whether blocking these specific channels influences the
inflammatory response.
In 2006, Roselli et al. reviewed the role of VGSC blockers as
immunomodulators52. Electrophysiological recordings have revealed the presence of
VGSC in microglial cells and macrophages90. Expression of VGSC in non-excitable cells
fluctuates depending on the state of the cell90,91. Additionally, some studies have shown
that VGSC specific drugs have reduced the amount of proinflammatory cytokines
released from microglia90. It has been shown that in microglial cells Na+ flux is
necessary for their activation because Na+ free media or VGSC blockers inhibited their
activation. Additionally, this diminished activation is proposed to be due to decreased
intracellular Na+ concentrations which will affect the exchange of ions through the
Na+/Ca2+ exchanger14,90,91. If this ion channel has diminished activity, then there will be
reduced levels of intracellular Ca2+ concentrations which would be associated with
decreased activation of microglial cells and macrophages by extension 14,90,91. As stated,
stress stimuli such as changes in intracellular Ca2+ concentrations affect the MAPK
signaling pathway to decrease proinflammatory cytokine gene expression14. Figure 5
depicts how sodium channel activity also affects intracellular calcium concentrations.
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Ion channel activity in cells is complex, and it has diverse effects on the function of cells.
Further study will need to be done to understand how inhibition of ion channels affects
the inflammatory response.

Figure 5. Schematic Depicting the Contribution of Sodium Channels to
Intracellular Ca2+ Concentrations. Depolarization of the microglial cell membrane
activates the voltage-gated sodium channel (NaV) allowing Na+ to enter the cell.
Increased intracellular Na+ concentrations reverses activity of the Na+/Ca2+ exchanger
(NCX) to increase intracellular calcium concentrations. This increase contributes to
effector functions of the cell. Blockage of Nav with TTX and NCX with KB-R7943
decreases intracellular calcium concentrations91. [Modified from Persson et al. (2014)].
Sodium-Hydrogen Antiporter 1.
The sodium-hydrogen antiporter 1 (NHE1) is known to be expressed in multiple
cell types, and there is data to suggest that it contributes to inflammatory responses 92. It
has been shown that inhibition of NHE1 inhibits NF-κB activation and IL-6 production in
ischemia-reperfusion injury models92. Inhibition of the antiporter also reduced
proinflammatory cytokine levels in the serum of septic rats, and it attenuated secretion
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of IL-1β and TNF-α from LPS-activated alveolar epithelium by decreased
phosphorylation of the IκB-α92. Furthermore, in intestinal tract epithelial cells, there was
a reduction in proinflammatory cytokine release with specific inhibition of NHE1 to
minimize NF-κB and p38 MAPK activation92. It is possible that lidocaine affects
leukocytes by changing the intracellular pH by inhibiting the Na+/H+ antiporter93. Here is
further evidence that another sodium transporter has been connected to the
inflammatory response, and inhibition of NHE1 attenuates proinflammatory cytokine
release.
Potential Role for Calcium Channels
Store-Operated Calcium Entry.
Increases in intracellular calcium concentrations activate lymphocytes specifically
microglial cells19,91. These changes also contribute to the effector functions of microglial
cells that include migration and release of cytokines and chemokines to mediate the
inflammatory response91. Influx of Ca2+ into lymphocytes is primarily mediated by storeoperated calcium entry (SOCE) and calcium-release activated calcium channels
(CRAC)19. There is constant seepage of calcium ions from the ER that are returned via
the SOCE mechanism94. Effector functions of microglial cells such as phagocytosis and
cytokine secretion that are induced by activation with LPS require sustained high
intracellular concentrations of Ca2+ 19.
Additionally, one study conducted by Heo et al. showed that the use of
pharmacological inhibitors and knockdown of these calcium channels resulted in a
decrease in the amount of TNF-α and IL-6 that were released from activated microglial
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cells19. Under regular cellular conditions, activity of calcium channels needs to be
regulated because sustained high intracellular concentrations of Ca 2+ cause cell
death19. Data from this study showed that SOCE activity is required for the release of
cytokines especially IL-6 from activated microglia19. Overall, the literature suggests that
calcium channels contribute to activation of the inflammatory response and release of
proinflammatory cytokines. Here is another potential target for drug anti-inflammatory
activity.
Potential Role for Potassium Channels
Several studies have found that amide local anesthetics including lidocaine
interact with K+ channels10. It has been shown that blocking of potassium channels
inhibits NF-κB activation10. One study found that in myelinated neurons lidocaine
decreased K+ channel activity by reducing the probability that the channel was in its
open state95. Lidocaine most likely blocks K+ channels from inside the cell because
adding the positively charged analog of lidocaine, QX-314, intracellularly blocks channel
activity to the same extent as lidocaine95. QX-314 applied extracellularly is unable to
block the pore suggesting that it is necessary for lidocaine to be able to cross the cell
membrane to act on an intracellular target95. Computer simulations have also found that
snake venom derived polypeptides can bind to the outer portion of a K + to block ion
flow3. Potassium channel blockade is another potential mechanism that antiinflammatory drugs may to decrease cytokine release from activated macrophages or
microglia.
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Conclusion
Recently, therapeutics have been identified for their anti-inflammatory properties.
These drugs include lidocaine and Zep peptides 3/4. In our model, we plan to test
whether lidocaine and Zep peptides attenuate proinflammatory cytokine release from
LPS and ATP activated human differentiated THP-1s. If they do attenuate cytokine
release, then the primary question will be what is their mechanism of action? There is
plenty of evidence in the literature that sodium, calcium, and potassium channel activity
all contribute to some degree to the activation of inflammation. Which channels are
involved in the anti-inflammatory effect of lidocaine or Zep peptides? Overall, the
literature lacks a well-defined hypothesis for the mechanism for how these newly
identified drugs attenuate the inflammatory response. In the following chapters, we will
address these questions to enrich our understanding of inflammatory pathways: how
they are regulated and what cellular targets are implicated in this response.

CHAPTER THREE
MATERIALS AND METHODS
Lidocaine Attenuates Proinflammatory Cytokine Release from Activated
Macrophages
Cell Culture.
THP-1s, a human monocyte cell line, were obtained from American Type Culture
Collection (ATCC). The THP-1 cells were cultured in Roswell Park Memorial Institute
(RPMI) 1640 media, supplemented with 10% characterized fetal bovine serum (FBS)
from Gibco, 100 IU/mL penicillin, 1 mg/mL streptomycin, and 10 ug/mL ciprofloxacin
hydrochloride. Characterized FBS was used because it has lower levels of endotoxins
compared to standard FBS to reduce background activation in the following assays. The
cells were cultured at 37° C with 5% carbon dioxide.
THP-1 cells were differentiated into macrophage-like cells by treating with 100
ng/mL phorbol 12-myristate 13-acetate (PMA) for 24 or 48 hrs. The cells rested for 4872 hrs before treatment to reduce background activation from PMA differentiation of the
proinflammatory genes of interest.
Quantification of IL-1β Secretion by ELISA.
THP-1 cells were plated at 500,000 cells per well in a 24-well plate with 100
ng/mL PMA for 24 hrs to differentiate the monocytes into macrophages. After
approximately 36 hrs, the differentiated macrophages were pretreated with 1 mM
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lidocaine hydrochloride for 16 hrs (Sigma-Aldrich). At the end of the pretreatment, some
wells had a media change, were treated again with 1 mM lidocaine, or previously
untreated wells were treated with 1 mM lidocaine. Then to activate TLR4 signaling, 10
ng of LPS was added for 4 hrs. A media change was done then 5 mM ATP was added
to initiate NLRP3 inflammasome formation. After 3.5 hrs, the supernatant was collected
from each sample. This experiment was repeated at least three times unless otherwise
noted.
In a second set of experiments following the same basic protocol as described
above, the treatments differed in the following ways: the cells were either pretreated for
30 minutes with 1 mM lidocaine before the addition of 10 ng LPS, were pretreated for 16
hrs with 1 mM lidocaine then treated with 1 mM lidocaine before the addition of 10 ng
LPS or were treated with 5 mM ATP only as a control. LPS treatment was for 4 hrs., and
ATP treatment was for 3.5 hrs. Then the supernatant was collected. This experiment
was repeated at least three times unless otherwise noted.
The samples were analyzed following the manufacturer’s instructions for the
R&D Systems Human IL-1 beta/IL-1F2 DuoSet ELISA. The plate was read using the
Gen 5 Plate Reader software. The standard curve was fit with a 4-parameter logistic
curve. The fit equation was generated and the sample concentrations of IL-1β were
predicted using the Gen 5 Plate Reader software.
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RT-PCR Analysis of Proinflammatory Cytokine Gene Expression.
THP-1 cells were plated at a density of 500,000 cells/well in a 24 well plate with
100 ng/mL PMA and RPMI media to differentiate the monocytes into macrophages.
After 24 hrs, the RPMI media was replenished, and the cells rested for 36 hrs. Then the
cells were treated with 1 mM of lidocaine hydrochloride for 16 hrs (Sigma-Aldrich).
Some wells had a media change, then 1 mM lidocaine was added immediately prior to
the addition of 10 ng of LPS in the appropriate wells. After 4 hrs, the media was
changed, and 5 mM ATP was added in the indicated wells. After 3.5 hrs, the cell lysate
was collected.
The RNA was isolated following the manufacturer’s protocol for the Nucleospin
RNA Plus kit (Macherey-Nagel). The RNA was then reverse transcribed to the
complementary DNA (cDNA) sequence using an oligodeoxythymidylic acid primer
following the manufacturer’s protocol (Promega). Real-time PCR (RT-PCR) was
performed on the cDNA with iTaqTM Universal SYBR® Green Supermix (Bio-Rad). PCR
was performed at 50°C for 2 minutes, 95°C for 10 minutes, followed by 40 cycles of
95°C for 30 seconds then 50°C for 1 minute. GAPDH was the housekeeping gene for
normalization. The primer set used to amplify GAPDH was 5’GCACCGTCAAGGCTGAGAAC-3’ for the 5’ primer and 5’GCCTTCTCCATGGTGGTGAA-3’ for the 3’ primer. The primer set used to amplify IL-6
was 5’-GGAGACTTGCCTGGTGAAAA-3’ for the 5’ primer and
5’ATCTGAGGTGCCCATGCTAC-3’ for the 3’ primer. The primer set used to amplify
proIL-1β was 5’-AATCTGTACCTGTCCTGCGTGTT-3’ for the 5’ primer and 5’-
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TGGGTAATTTTTGGGATCTACACTCT-3’ for the 3’ primer. The mRNA levels of both
IL-6 and proIL-1β were normalized to the GAPDH mRNA levels. Fold change in gene
expression was calculated using the 2-ΔΔCt method was used.
Statistical Analyses.
GraphPad Prism software (GraphPad Software, San Diego, CA) was used to
conduct the statistical analyses. In most cases a one-way ANOVA was performed using
the Tukey multiple comparison test (the mean of each group was compared to the mean
of every other group). All the reported values are reported as mean ± SEM. Each
experiment was performed at least three times unless otherwise noted.
Zep 3 and Zep 4 Peptides Attenuate Proinflammatory Cytokine Release from
Activated Macrophages
Cell Culture.
THP-1s, a human monocyte cell line, were obtained ATCC. The THP-1 cells
were cultured in RPMI 1640 media, supplemented with 10% characterized FBS from
Gibco, 100 IU/mL penicillin, 1 mg/mL streptomycin, and 10 ug/mL ciprofloxacin
hydrochloride. Characterized FBS was used for the reasons described above. The cells
were cultured at 37° C with 5% CO2.
THP-1 cells were differentiated into macrophage-like cells by treating with 100
ng/mL PMA for 24 or 48 hrs. The cells rested for 48-72 hrs before treatment to reduce
background activation from PMA differentiation of the proinflammatory genes of interest.
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Quantification of IL-1β Secretion by ELISA.
THP-1 cells were plated at 500,000 cells per well in a 24-well plate with 100
ng/mL PMA for 24 hrs to differentiate the monocytes into macrophages. After
approximately 36 hrs, the differentiated macrophages were pretreated with 12 ug/mL
Zep 3 or 50 ug/mL Zep 4 for 16 hrs (Dr. Bruce Gaynes, Loyola University Chicago). At
the end of the pretreatment, some wells had a media change, were treated again with
12 ug/mL Zep 3 or 50 ug/mL Zep 4, or previously untreated wells were treated with 12
ug/mL Zep 3 or 50 ug/mL Zep 4. Then to activate TLR4 signaling, 10 ng of LPS was
added for 4 hrs. A media change was done then 5 mM ATP was added to initiate
NLRP3 inflammasome formation. After 3.5 hrs, the supernatant was collected from each
sample. The samples were analyzed following the manufacturer’s instructions for the
R&D Systems Human IL-1 beta/IL-1F2 DuoSet ELISA. The plate was read using the
Gen 5 Plate Reader software. The standard curve was fit with a 4-parameter logistic
curve. The fit equation was generated and the sample concentrations of IL-1β were
predicted using the Gen 5 Plate Reader software.
RT-PCR Analysis of Proinflammatory Cytokine Gene Expression.
THP-1 cells were plated at a density of 500,000 cells/well in a 24 well plate with
100 ng/mL PMA and RPMI media to differentiate the monocytes into macrophages.
After 24 hrs, the RPMI media was replenished, and the cells rested for 36 hrs. Then the
cells were treated with 12 ug/mL Zep 3 or 50 ug/mL Zep 4 for 16 hrs (Dr. Bruce Gaynes,
Loyola University Chicago). Some wells had a media change, then 12 ug/mL Zep 3 or
50 ug/mL Zep 4 was added immediately prior to the addition of 10 ng of LPS in the

39

appropriate wells. After 4 hrs, the media was changed, and 5 mM ATP was added in the
indicated wells. After 3.5 hrs, the cell lysate was collected.
The RNA was isolated following the manufacturer’s protocol for the Nucleospin
RNA Plus kit (Macherey-Nagel). The RNA was then reverse transcribed to the
complementary DNA (cDNA) sequence using an oligodeoxythymidylic acid primer
following the manufacturer’s protocol (Promega). Real-time PCR (RT-PCR) was
performed on the cDNA with iTaqTM Universal SYBR® Green Supermix (Bio-Rad). PCR
was performed at 50°C for 2 minutes, 95°C for 10 minutes, followed by 40 cycles of
95°C for 30 seconds then 50°C for 1 minute. GAPDH was the housekeeping gene for
normalization. The primer set used to amplify GAPDH was 5’GCACCGTCAAGGCTGAGAAC-3’ for the 5’ primer and 5’GCCTTCTCCATGGTGGTGAA-3’ for the 3’ primer. The primer set used to amplify IL-6
was 5’-GGAGACTTGCCTGGTGAAAA-3’ for the 5’ primer and
5’ATCTGAGGTGCCCATGCTAC-3’ for the 3’ primer. The primer set used to amplify
proIL-1β was 5’-AATCTGTACCTGTCCTGCGTGTT-3’ for the 5’ primer and 5’TGGGTAATTTTTGGGATCTACACTCT-3’ for the 3’ primer. The mRNA levels of both
IL-6 and proIL-1β were normalized to the GAPDH mRNA levels. Fold change in gene
expression was calculated using the 2-ΔΔCt method was used.
Optimized Differentiation of THP-1s into Human Macrophage-like Cells
Cell Culture.
THP-1s, a human monocyte cell line, were obtained ATCC. The THP-1 cells
were cultured in RPMI 1640 media, supplemented with 10% characterized FBS from
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Gibco, 100 IU/mL penicillin, 1 mg/mL streptomycin, and 10 ug/mL ciprofloxacin
hydrochloride. Characterized FBS was used for the reasons described above. The cells
were cultured at 37° C with 5% CO2.
THP-1 cells were differentiated into macrophage-like cells by treating with 100
ng/mL PMA for 24 or 48 hrs. The cells rested for either 24 hrs, 48 hrs, 72 hrs, or 96 hrs
before treatment to find the optimal time when background activation from PMA
differentiation is at its lowest.
Cell Imaging.
The cells were imaged after 24 hrs. or 48 hrs. of PMA differentiation. The cells
were again imaged after 24 hrs., 48 hrs., 72 hrs., and at 96 hrs. of rest following
differentiation. The changes in morphology at each of these time points was noted. The
cells were imaged using a confocal microscope.
RT-PCR Analysis of Proinflammatory Cytokine Gene Expression.
THP-1 cells were plated at a density of 500,000 cells/well in a 24 well plate with
100 ng/mL PMA and RPMI media to differentiate the monocytes into macrophages.
After 24 hrs. or 48 hrs., the RPMI media was replenished, and the cells rested for 24
hrs., 48 hrs., 72 hrs., or 96 hrs. The appropriate wells were then treated with 10 ng of
LPS to upregulate proinflammatory cytokine gene expression. After 4 hrs, the cell lysate
was collected.
The RNA was isolated following the manufacturer’s protocol for the Nucleospin
RNA Plus kit (Macherey-Nagel). The RNA was then reverse transcribed to the
complementary DNA (cDNA) sequence using an oligodeoxythymidylic acid primer
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following the manufacturer’s protocol (Promega). Real-time PCR (RT-PCR) was
performed on the cDNA with iTaqTM Universal SYBR® Green Supermix (Bio-Rad). PCR
was performed at 50°C for 2 minutes, 95°C for 10 minutes, followed by 40 cycles of
95°C for 30 seconds then 50°C for 1 minute. GAPDH was the housekeeping gene for
normalization. The primer set used to amplify GAPDH was 5’GCACCGTCAAGGCTGAGAAC-3’ for the 5’ primer and 5’GCCTTCTCCATGGTGGTGAA-3’ for the 3’ primer. The primer set used to amplify IL-6
was 5’-GGAGACTTGCCTGGTGAAAA-3’ for the 5’ primer and
5’ATCTGAGGTGCCCATGCTAC-3’ for the 3’ primer. The primer set used to amplify
proIL-1β was 5’-AATCTGTACCTGTCCTGCGTGTT-3’ for the 5’ primer and 5’TGGGTAATTTTTGGGATCTACACTCT-3’ for the 3’ primer. The mRNA levels of both
IL-6 and proIL-1β were normalized to the GAPDH mRNA levels. Fold change in gene
expression was calculated using the 2-ΔΔCt method was used.

CHAPTER FOUR
LIDOCAINE ATTENUATES PROINFLAMMATORY CYTOKINE RELEASE FROM
ACTIVATED MACROPHAGES
Introduction: IL-1β Secretion from Lidocaine Treated Macrophages
Recently, local anesthetics such as lidocaine have been identified for their
potential anti-inflammatory effects on activated macrophages or microglial cells. Within
the context of pain relief, lidocaine acts on voltage-gated sodium channels2. However,
the canonical inflammatory pathways including TLR4 signaling and NLRP3
inflammasome activation do not include a defined role for ion channels aside from
potassium efflux that initiates inflammasome formation upon ATP activation of the P2X7
receptor.
Briefly, several studies have shown that lidocaine attenuates proinflammatory
cytokine release from macrophages and other cell types in different inflammatory
disease models4–14. In the literature, various inflammatory stimuli were used, and
lidocaine treatment reduced cytokine release to different degrees4–14. In one study,
mouse microglial cells were treated with LPS and IFN-γ to cause endotoxemia and
subsequent inflammation6. A positively charged lidocaine analog that cannot cross the
plasma membrane was used6. The data showed a slight decrease in IL-1β release but
no change in TNF-α from the lidocaine treated cells compared to the positive control6. In
contrast, another study showed a more significant decrease in TNF-α and IL-1β release
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from LPS-activated and lidocaine treated rat microglial cells4. Additionally, rat microglial
cells were stimulated with 1 mM ATP only for 2 hrs and lidocaine 14. With lidocaine
treatment, there was a dose-dependent decrease in TNF-α, IL-1β, and IL-614. In
general, there is some discrepancy in the literature regarding the degree of lidocaine’s
anti-inflammatory effect on proinflammatory cytokine release.
Overall, several studies have been done to understand the effect lidocaine has
on microglial cells and other cell types that have been stimulated by different
combinations of inflammatory signals. Generally, these studies showed that lidocaine
treatment attenuated the release of IL-6, TNF-α, and IL-1β. However, none of these
studies have used a more broadly applicable model human cell line nor have the cells
been stimulated by both LPS and ATP which are commonly used stimuli of the
canonical TLR4 signaling and NLRP3 inflammasome activation.
Based on the literature and some preliminary experiments, we hypothesized that
if lidocaine has an anti-inflammatory effect on activated macrophages then there will be
attenuated release of the proinflammatory cytokine, IL-1β, from these cells. To expand
upon what is currently known about lidocaine’s anti-inflammatory effect, we used
differentiated THP-1s which are an immortalized human macrophage-like cell line.
Additionally, we used both LPS to initially prime the TLR4 MyD88-dependent signaling
pathway to upregulate the gene expression of proIL-1β. Then ATP was used as the
second signal to trigger inflammasome complex formation and cleavage of proIL-1β into
its mature, secreted form. It has been shown that monocytes that were only activated
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with a priming signal released less than 10% of the IL-1β that had accumulated in the
cytosol22. In our experiments, we measured IL-1β released in the supernatant after two
activating signals which gave us higher concentrations of the cytokine release
compared to other studies.
The differentiated THP-1s cells were either pretreated with lidocaine for 16 hrs.
before activation and/or a lidocaine treatment at the time of LPS activation. These
different timepoints of treatment allow for an understanding of whether there are
temporal restraints on lidocaine’s anti-inflammatory effect on these cells. If lidocaine
pretreatment reduces IL-1β release, then the effect will not be directly due to ion flux,
suggesting a mechanism that affects cellular signaling. In contrast, if lidocaine treatment
at the time of LPS attenuates IL-1β release, then lidocaine has a rapid, direct antiinflammatory effect comparable to its rapid analgesic response. Again, if lidocaine
diminishes proinflammatory cytokine release, then with lidocaine treatment we would
expect significantly reduced levels of IL-1β compared to LPS and ATP treatment only.
Experimental Design: Quantification of IL-1β Release
WT THP-1s were plated at a cell density of 500,000 cells/well in a 24 well plate
with 100 ng/mL PMA to differentiate the cells for 24 or 48 hrs. At this time, the media
was replaced with fresh RPMI containing Characterized FBS. The cells were then
allowed to rest for 36 hrs (after 24 hrs PMA differentiation) or 60 hrs (after 48 hrs PMA
differentiation). Lidocaine (1 mM) was added for the 16 hr pretreatment. After the
pretreatment, the media was changed in the indicated wells. Then lidocaine (1 mM) was
added immediately prior to the addition of 10 ng LPS. After 4 hrs, the media was
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changed, and 5 mM of ATP was added to the appropriate wells for 3.5 hrs. Then the
supernatant was collected to quantify the amount of IL-1β that was released using a
sandwich ELISA (R&D Systems Human IL-1 beta/IL-1F2 DuoSet ELISA). This
experiment was repeated at least three times unless otherwise noted. In a second set of
experiments following the same basic protocol as described above, the treatments
differed in the following ways: the cells were either pretreated for 30 minutes with 1 mM
lidocaine before the addition of 10 ng LPS, were pretreated for 16 hrs with 1 mM
lidocaine then treated with 1 mM lidocaine before the addition of 10 ng LPS or were
treated with 5 mM ATP only as a control. This experiment was repeated at least three
times unless otherwise noted.
Results: Quantification of IL-1β Release
To establish if lidocaine has anti-inflammatory effects on activated macrophages,
we chose to use an overnight pretreatment and a lidocaine treatment at the time of LPS
addition. This treatment plan allowed for an understanding of whether a pretreatment
was required or if lidocaine had an immediate effect. When lidocaine acts as a numbing
agent, its effects are more immediate. In that context, lidocaine directly blocks the
voltage-gated sodium channels in neurons. This blockade prevents the neuron from
firing and signaling pain. The question here was whether lidocaine initiates a cascade of
signaling to minimize an induced inflammatory response over time or does lidocaine’s
interaction with a cellular target immediately reduce release of proinflammatory
cytokines. We hypothesized that the drug more likely initiates a change in signaling to
reduce an inflammatory response because inflammation is activated and regulated by
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several signaling pathways. In contrast, the pain response is mediated directly by ion
channel activity as evidenced by lidocaine’s known blockade of sodium ion flux.
As expected, no treatment of differentiated THP-1s resulted in minimal release of
IL-1β. LPS and ATP treatment caused a significant increase in IL-1β release (Figure 6).
All lidocaine pretreatments attenuated IL-1β release by approximately a 3-fold reduction.
Interestingly, the lidocaine pretreatment with a media change before LPS stimulation
also reduced release of the cytokine. These results suggested that lidocaine causes
changes in the cell that are still altered at the time of treatment with the proinflammatory
signals to minimize the response to those stimuli. It was unexpected that a lidocaine
pretreatment then media change would still affect the responsiveness of the cell to the
inflammatory signals. A possible explanation is that lidocaine is acting intracellularly and
was unaffected by a media change. This explanation is also reasonable because at
physiological pH lidocaine is in both its charged and uncharged forms3. Its uncharged
form can pass the plasma membrane and act intracellularly in either its positive or
uncharged form or the charged form can target the cell surface.
This experiment also demonstrated that lidocaine treatment at the time of LPS
addition does not have an anti-inflammatory effect on these cells as evidenced by no
difference between the amount of IL-1β released from this lidocaine treatment
compared to the LPS and ATP only control. These results do not support the idea that
lidocaine has an immediate effect perhaps through direct changes in ion flux to
attenuate the inflammatory response. The data suggested that changes in ion flux are
not directly responsible for reducing differentiated THP-1 response to LPS and ATP. In
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the case where cells were treated with both a lidocaine pretreatment and lidocaine at
the time of signal 1, there was release of IL-1β comparable to the amount of IL-1β
released from cells only pretreated with lidocaine. Taken together, the effect on the
twice lidocaine treated differentiated THP-1s was likely due primarily to the lidocaine
pretreatment since the lidocaine treatment at the time of LPS did not result in reduced
cytokine secretion.

Figure 6. Lidocaine Pretreatment Reduces IL-1β Release from LPS and ATP
Activated Macrophages. Differentiated THP-1s were treated with 1 mM lidocaine 16
hrs. prior to LPS activation and/or at the time of LPS activation. After 4 hrs., the media
was changed, and 5 mM ATP was added to the appropriate wells. After 3.5 hrs., the
supernatant was collected, and an ELISA was performed to measure the amount of IL1β secreted. This image was representative of three independent experiments.
One challenge of working with THP-1s is that there can be a lot of variability in
responsiveness to stimuli and drug treatment between cell cultures and experiments. To
address these differences, Figure 7 shows the average of 10 independent lidocaine
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experiments with either the 16 hrs. lidocaine pretreatment and treatment at the time of
LPS or lidocaine treatment at the time of LPS only. Furthermore, the raw maximum
concentration of IL-1β released from can vary greatly, so here the data are represented
as fold change in IL-1β secretion. Across experiments, there is a significant reduction in
IL-1β release from lidocaine pretreated cells, and there is a slight decrease in IL-1β
release from lidocaine treated cells at the time of LPS. Even with the variability
associated with THP-1s (discussed further in Chapter 7), lidocaine pretreatment
significantly attenuated the release of IL-1β to levels comparable to no treatment. Even
lidocaine treatment at the time of LPS slightly reduces cytokine release which is not as
evident when looking at the results from only one experiment. Overall, the lidocaine
pretreatment consistently reduced the amount of IL-1β released to approximately 17 ±
7% of the amount released by LPS and ATP only.
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Figure 7. Lidocaine Treatment Significantly Reduced the Average Fold Change in
IL-1β Secretion from LPS and ATP Activated Differentiated THP-1s. Differentiated
THP-1s were treated with 1 mM lidocaine 16 hrs. prior to LPS activation and/or at the
time of LPS activation. After 4 hrs., the media was changed, and 5 mM ATP was added
to the appropriate wells. After 3.5 hrs., the supernatant was collected, and an ELISA
was performed to measure the amount of IL-1β secreted. This graph was representative
of ten independent experiments. Data were analyzed by one-way ANOVA with Tukey’s
post-hoc test. Error bars indicated standard error of the mean.
The 16 hrs. pretreatment raised the question of whether it was lidocaine itself
that had the anti-inflammatory effect or if it could potentially be a metabolite or some
other factor that caused reduction in cytokine release. To address this question, cells
were pretreated with lidocaine for 30 mins. before the addition of LPS and later ATP.
This timepoint was chosen because in the clinical setting patients receive a lidocaine
injection approximately 30 mins. before a procedure when numbing is required26. If
lidocaine has an anti-inflammatory effect with a 30 mins. pretreatment before initiation of
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an inflammatory response, then patients who received a lidocaine injection before
treatment may also have the added benefit of less inflammation as part of the healing
process and less inflammation-associated pain. Lidocaine may have a dual function of
providing immediate pain relief during surgery, but also limiting later inflammation
caused by the tissue injury.
The second challenge to be addressed was that proIL-1β is highly expressed in
untreated differentiated THP-1s. As THP-1s are in culture, we noticed that they have
increased expression of proinflammatory genes over time. We think these changes
relate to how sometimes with lidocaine treatment the amount of IL-1β released is more
comparable to no treatment levels but in other experiments the release is not as
attenuated. An ATP control only allowed us to appreciate the quantity of IL-1β cleaved
by ATP that solely depends on basal expression of proIL-1β.
The data showed that a 30 min lidocaine pretreatment attenuated IL-1β release
from activated macrophages to approximately the same degree as the 16 hrs. lidocaine
pretreatment with a second lidocaine treatment at the time of LPS (Figure 8). Moreover,
the differentiated THP-1s treated with ATP only released a quantity of IL-1β that was not
very different from the lidocaine treatment. These results suggested that with a clinically
relevant lidocaine pretreatment of 30 mins. there were decreased levels of IL-1β
released from activated macrophages.
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Figure 8. A Clinically Relevant Lidocaine Pretreatment and an ATP Only Control
Reduced Release of IL-1β Compared to LPS and ATP Activated Differentiated
THP-1s. Differentiated THP-1s were treated with lidocaine 30 min. before LPS or
treated with lidocaine overnight and at the time of LPS. After 4 hrs., the cells were
additionally treated with ATP or ATP only as a control. After 3.5 hrs., the supernatant
was collected, and an ELISA was performed to measure IL-1β release. Data were
analyzed by one-way ANOVA with Tukey’s post-hoc test. Error bars indicated standard
error of the mean.
Introduction: Quantification of Proinflammatory Cytokine Gene Expression
To begin to understand the mechanism through which lidocaine attenuated
release of the proinflammatory cytokine, IL-1β, we decided to quantify the fold change in
gene expression of IL-6 and proIL-1β. ProIL-1β requires two signals for it to be released
from the cell. Release of IL-1β requires upregulation of its expression and activation of
the NLRP3 inflammasome to cleave it into its mature, secreted form. In contrast, IL-6
release does not require a second signal for its release from activated macrophages 28.
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It contains a signal sequence that marks it for conventional secretion28. As mentioned
earlier, proIL-1β is highly expressed in untreated differentiated THP-1s, meaning that
upon activation with LPS there was a smaller increase in gene expression of this
cytokine. In contrast, IL-6 is minimally expressed in untreated macrophage-like THP-1s,
so upon LPS treatment, there is a significant increase in IL-6 gene expression. In these
experiments, we used two signals to activate these pathways to establish a model in our
lab that can be used to test a variety of potential anti-inflammatory drugs. Activating the
differentiated THP-1s with both LPS and ATP will allow us to begin to elucidate
lidocaine’s mechanism of action.
In the literature, a decrease in proinflammatory cytokine gene expression with
lidocaine treatment accounts for at least part of the reduction in secretion of TNF-α,
proIL-1β, and IL-68,10. In rat microglial cells stimulated with ATP only, there was a dosedependent decrease in gene expression of these cytokines with lidocaine treatment14. A
second study used LPS only to activate TLR4 signaling, and the data showed that there
was a decrease in gene expression of TNF-α and proIL-1β with lidocaine treatment4.
Even though there is some evidence in the literature showing that lidocaine reduces
proinflammatory cytokine gene expression, the extent of this reduction is rather minimal.
As a result, perhaps the reduction in gene expression is not the only factor contributing
to reduced proinflammatory cytokine release.
Furthermore, in the literature, there are two main pathways that are commonly
studied in relation to gene expression of proinflammatory cytokines4,14. In the canonical
inflammatory pathway, activation of TLR4 signaling leads to the translocation of the
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transcription factor, NF-κB, into the nucleus where it binds to DNA and upregulates
gene expression related to several cellular processes18,19. Additionally, the MAPK
signaling pathway responds to stress stimuli such as changes in intracellular cation
concentrations to activate downstream transcription factors that also regulate gene
expression30. If lidocaine acts through a mechanism that inhibits or downregulates these
pathways, then we would expect reduced gene expression of proIL-1β and IL-6.
Experimental Design: Quantification of Proinflammatory Cytokine Gene
Expression
We will again use THP-1s plated at a density of 500,000 cells/well in a 24 well
plate. They were differentiated with 100 ng/mL of PMA for 24 hrs then allowed to rest for
36 hrs in fresh RPMI medium. The cells were either pretreated with 1 mM lidocaine for
16 hrs and/or with 1 mM lidocaine at the time of LPS treatment. The cells were treated
with 10 ng of LPS for 4 hours then with 5 mM of ATP for 3.5 hrs. The cell lysate was
collected. Then RNA isolation, cDNA conversion, and RT-PCR were performed on each
of the samples. These RT-PCR analyses were performed on the same treated cells
whose supernatant was collected for the previously described ELISA experiments. This
experimental approach allowed for comparisons to be made between changes in gene
expression and the amount of protein released. Each experimental condition was
repeated at least 3 times unless otherwise noted.
In a second set of experiments, the protocol above was followed, but the
treatments were different in the following ways: the differentiated THP-1s were
pretreated for 30 mins. with 1 mM lidocaine before the addition of 10 ng LPS, the cells
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were pretreated for 16 hrs with 1 mM lidocaine and again with 1 mM lidocaine at the
time of 10 ng LPS treatment or the cells were treated with 5 mM ATP only for 3.5 hrs.
Each experimental condition was repeated at least 3 times unless otherwise noted.
Results: Quantification of Proinflammatory Cytokine Gene Expression
Our first step towards understanding how lidocaine attenuated proinflammatory
cytokine release was to measure gene expression for proIL-1β and IL-6. If there was
less expression of these genes in lidocaine treated cells, we would begin to understand
one of the contributing factors that accounted for lidocaine’s anti-inflammatory effect on
human macrophage-like cells. We would expect the fold change in cytokine gene
expression of lidocaine treated cells to be comparable to no treatment if lidocaine
inhibited or downregulated the NF-κB and MAPK signaling pathways.
The fold change in gene expression was normalized to the no treatment
expression of each of the proinflammatory cytokine genes. There was significant
upregulation of gene expression of proIL-1β and IL-6 when the differentiated THP-1s
were treated with both LPS and ATP (Figure 9 A. & B.). There was far greater fold
increase in IL-6 expression with LPS and ATP treatment compared to proIL-1β. This
difference was likely due to there being high expression of proIL-1β in untreated
differentiated THP-1s compared to relatively low expression of IL-6 in these cells. Upon
activation, IL-6 was more upregulated than proIL-1β due to differences in their basal
expression.
In the case of proIL-1β, a 16 hrs. lidocaine pretreatment followed by a media
change before either a second lidocaine treatment or the addition of LPS resulted in a
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decrease in gene expression comparable to no treatment. With the other lidocaine
pretreatments, there was also a downregulation in proIL-1β, but not to the same extent
(Figure 9. A.). These results suggested that the reduction in IL-1β release from activated
macrophages was at least in part due to a downregulation of the cytokine’s gene
expression. With the lidocaine treatment at the time of LPS, there was no significant
change in gene expression between that treatment and the LPS and ATP only
treatment (Figure 9. A.). These data suggested that the changes in IL-1β release from
activated macrophages was perhaps dependent on lidocaine having time to reach its
target to initiate downregulation signaling of proinflammatory cytokine gene expression.
Similar trends were seen with IL-6 gene expression (Figure 9. B.). With the
lidocaine pretreatments consisting of a 16 hrs. pretreatment and/or a second lidocaine
treatment at the time of LPS addition, there was a reduction in IL-6 gene expression that
was comparable across all those treatment groups. Again, lidocaine treatment at the
time of LPS did not result in a change in IL-6 gene expression compared to the LPS and
ATP only control. For both genes analyzed by RT-PCR, there was a reduction in gene
expression with lidocaine pretreatment, but no change in gene expression when
lidocaine was added at the time of the initiation of the inflammatory response.
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Figure 9. Lidocaine Pretreatment Reduces Gene Expression of proIL-1β and IL-6
from LPS and ATP Activated Macrophages. Differentiated THP-1s were pretreated
with lidocaine for 16 hrs and/or were treated with lidocaine at the time of LPS treatment.
The macrophage-like cells were treated with LPS for 4 hrs. then ATP for 3.5 hrs. The
cell lysate was collected. The RNA was isolated, cDNA was made, and RT-PCR was
performed for each of the samples. These are representative images from at least three
independent experiments. A. Fold change in gene expression of proIL-1β. B. Fold
change in gene expression of IL-6.
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Figure 10. Lidocaine Pretreatment Significantly Reduced the Average Fold
Change in IL-1β Gene Expression from LPS and ATP Activated Differentiated
THP-1s. Differentiated THP-1s were pretreated with lidocaine for 16 hrs and/or were
treated with lidocaine at the time of LPS treatment. The macrophage-like cells were
treated with LPS for 4 hrs. then ATP for 3.5 hrs. The cell lysate was collected. The RNA
was isolated, cDNA was made, and RT-PCR was performed for each of the samples.
This graph was representative of ten independent experiments. Data were analyzed by
one-way ANOVA with Tukey’s post-hoc test. Error bars indicated standard error of the
mean.
As described earlier, working with THP-1s can be challenging because there are
differences in how responsive the cells are between experiments and between cell
cultures. These challenges were again addressed by averaging the gene expression of
proIL-1β for the corresponding 10 independent lidocaine experiments that were shown
in Figure 7. The differentiated THP-1s were treated with either a 16 hrs. lidocaine
pretreatment and treatment at the time of LPS or lidocaine treatment at the time of LPS
only. Between experiments, there was a significant reduction in proIL-1β gene
expression from lidocaine pretreated cells, but there was no significant decrease in
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proIL-1β gene expression from cells treated with lidocaine at the time of LPS (Figure
10). Overall, the data suggested that lidocaine pretreatment attenuated IL-1β release at
least in part by reducing this cytokine’s gene expression.
Moreover, corresponding to the ELISA data where a 30 mins. lidocaine
pretreatment and an ATP only control were tested, the cell lysate from those
experiments was analyzed for changes in proinflammatory gene expression (Figure 11.
A. & B.). Again, the fold change was normalized for all treatment groups against no
treatment. With LPS and ATP treatment, there was upregulation of gene expression of
proIL-1β and IL-6 to roughly the same extent as in the previous set of experiments.
However, there was no reduction in gene expression of either proIL-1β or IL-6 for the 30
mins. lidocaine pretreatment or the 16 hrs. lidocaine pretreatment with a second
lidocaine treatment at the time of LPS addition. These results were somewhat
surprising, but they suggested that the reduction of IL-1β from lidocaine pretreated
differentiated THP-1s were likely not solely due to a reduction in cytokine gene
expression. As expected, there was only minimal upregulation of proIL-1β and IL-6 gene
expression for the ATP only treatment. These results were consistent with the results of
the earlier Su et al. study that showed there was marginal upregulation of
proinflammatory cytokine gene expression in ATP treated cells5. Taken together, these
data suggested that the reduction in IL-1β release from LPS and ATP activated
macrophages was partially due to a decrease in proinflammatory cytokine gene
expression.
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Figure 11. 30 min. Lidocaine Pretreatment and ATP Only Control Have No Effect
on Proinflammatory Cytokine Gene Expression. Differentiated THP-1s were
pretreated with lidocaine for 30 mins. or were pretreated for 16hrs and again at the time
of LPS. The cells were then activated with LPS for 4 hrs. and ATP for 3.5 hrs. In this
experiment, there was also an ATP only control. The cell lysate was collected. The RNA
was isolated, cDNA was made, and RT-PCR was performed on all samples. This is
representative data from one experiment that was performed at least 3 times for all
treatment groups. A. Fold change in gene expression of proIL-1β. B. Fold change in
gene expression of IL-6.
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Discussion
Our goal was to determine if lidocaine could attenuate proinflammatory cytokine
release from human macrophage-like cells. Several previous studies have analyzed
cytokine release from predominantly in vitro or in vivo mouse or rat models4–14. We
wanted to use a more relevant model in our studies, so we chose the human monocyte
cell line, THP-1s. We activated differentiated THP-1s with both LPS and ATP to provide
the two signals necessary for TLR4 signaling and NLRP3 inflammasome formation. The
use of these two signals in the same experiment was unique to our study. It allowed us
to begin to determine if lidocaine treatment affected activation of one or both signaling
pathways. To identify whether lidocaine attenuated proinflammatory cytokine release
from differentiated THP-1s, we measured IL-1β secretion by ELISA. Additionally, we
aimed to elucidate the mechanism of lidocaine’s anti-inflammatory effects. We
measured fold change in gene expression of proIL-1β and IL-6 by RT-PCR to determine
if lidocaine treatment downregulated cytokine gene expression. Overall, we
hypothesized that if lidocaine has anti-inflammatory effects on LPS and ATP activated
human macrophage-like cells, then it would attenuate proinflammatory cytokine release
by (1) inhibiting a cellular target to decrease intracellular cation concentrations and by
(2) reducing upregulation of proinflammatory cytokine gene expression mediated by NFκB and MAPK signaling.
Our data showed that lidocaine pretreatment was required for the most
significant decrease in IL-1β release compared to LPS and ATP activated cells.
Lidocaine treatment at the time of LPS did reduce cytokine release but to a minimal
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degree in comparison. The corresponding results for gene expression showed that
proIL-1β expression was downregulated closer to no treatment levels. Also, between
experiments, IL-6 expression for lidocaine pretreated cells was downregulated but to a
lesser extent than proIL-1β. Perhaps there were differences in the degree of the effect
of lidocaine treatment between genes because proIL-1β is highly expressed in these
cells so activation by LPS has a lesser effect than it does for IL-6. Furthermore, the
literature shows that IL-6 expression is regulated by a specific subunit of NF-κB that
differs from proIL-1β gene upregulation36. Lidocaine pretreatment may not affect
transcription of these cytokines in the same way.
Since our pretreatment was for 16 hrs., the question arose of whether lidocaine
was being metabolized in that time frame resulting in a metabolite being responsible for
the effect we saw. We tested a 30 min. lidocaine pretreatment to address this question.
This length of time is comparable to the amount of time lidocaine is applied before
surgery26. The results showed that a 30 min. pretreatment was sufficient to attenuate
cytokine release, but it had no significant effect on cytokine gene transcription. The data
suggested that downregulation of cytokine gene transcription was only one part of a
more complex mechanism that contributes to decreased cytokine secretion. Our results
showed that a clinically relevant pretreatment reduced the production of IL-1β,
suggesting that patients may experience less surgery-induced inflammation. Further
studies would be required to identify other ways that lidocaine reduces inflammatory
activation in our model.
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In the second set of experiments, an ATP only control was used to gain a sense
of how much released IL-1β came from the high basal expression level of proIL-1β. The
amount of the cytokine found in the supernatant from ATP only treated cells was slightly
less than the amount released from lidocaine, LPS, and ATP treated cells. The data
suggested that inflammasome activation and cleavage may still contribute significantly
to the amount of IL-1β released from lidocaine treated cells. Further experiments
focusing on NLRP3 inflammasome activation specifically would need to be done to
identify what effect lidocaine has on inflammasome formation.
One caveat of these experiments is their variability. Between experiments,
lidocaine has varying degrees of effect on the amount of IL-1β that is released from
these activated cells. One possible explanation is that there may be variability in the
differentiation of the WT THP-1s. Even though the procedure followed is the same each
time, perhaps the cells from different cultures and from cells with more passages in
cultures may respond differently to PMA. There is some suggestion in the literature that
less differentiated cells have a reduced number of ion channels20. If as we hypothesize
that lidocaine has an ion channel target, then perhaps in less differentiated cells, there
are fewer targets for lidocaine diminishing its effect. In experiments where we only see a
marginal effect with lidocaine treatment, those cells may have been less differentiated
and expressed fewer ion channels to reduce lidocaine’s anti-inflammatory effect.
A second possibility is that over time in culture these cells express more
proinflammatory cytokines at the basal level. As the cells become more
proinflammatory, stimulation with LPS has a smaller effect on transcription. Thus, the
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fold change in gene expression between the no treatment and LPS and ATP narrowed.
Perhaps under these conditions, lidocaine has less of an anti-inflammatory effect. There
was more fluctuation between experiments in terms of cytokine gene expression, but
that was likely related to changes in basal expression. Additionally, it was likely that
lidocaine’s anti-inflammatory effect resulted from other mechanisms besides
downregulation in proinflammatory cytokine gene expression. Nevertheless, as
evidenced by the average results from ten experiments, consistent results were seen in
how much IL-1β secretion decreased from lidocaine treated cells.
Lidocaine treatment at the time of LPS may not allow sufficient time for lidocaine
to access its target to reduce cytokine expression and secretion. Okura et al. found that
when oocytes were treated with lidocaine and ATP at the same time followed by a
second treatment of lidocaine after 5 minutes there was greater inhibition with the
second treatment suggesting that there was more time for lidocaine to access its
target53. The same may be true in our case where treatment of lidocaine immediately
before LPS may not allow enough time for lidocaine to reach its site of activity before
inflammation was induced.
From these experiments, we have shown that lidocaine pretreatment of short and
long duration attenuated release of IL-1β from LPS and ATP activated differentiated
THP-1s. This anti-inflammatory effect was partially due to downregulation of
proinflammatory cytokine gene expression, but it also was likely that other mechanisms
contributed to this effect.
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Future Directions
The next goal towards understanding lidocaine’s anti-inflammatory activity would
be to identify the cellular target of lidocaine. The inhibition of several ion channels has
been shown to reduce inflammatory responses as outlined in Chapter 2. To identify the
cellular target of lidocaine in this context, we have decided to use RNA-Seq. It is an
unbiased, global technique that detects all the genes that are either upregulated or
downregulated by lidocaine treatment compared to the LPS and ATP control. The
results can be analyzed by organizing the genes in their cellular pathways. The data
can generate hypotheses about lidocaine’s target and anti-inflammatory mechanism of
action.

CHAPTER FIVE
ZEP 3 and ZEP 4 PEPTIDES ATTENUATE PROINFLAMMATORY CYTOKINE
RELEASE FROM ACTIVATED MACROPHAGES
Introduction: IL-1β Secretion from Zep Peptide Treated Macrophages
In the literature, it has been shown that whole snake venom and peptides
isolated from the venom have analgesic and anti-inflammatory properties that need to
be better understood15–17,87. In several in vivo models, there was less IL-1β and TNF-α
in the serum of animals treated with NNAV or NT before activation of an inflammatory
response15,16. Peptides derived from snake venom have been used as alternative
medicines for centuries, but little is known still about how they have anti-tumor, antiinflammatory, anti-stroke, and analgesic effects15,87
Here, we used Zep peptides derived from snake venom obtained from Dr. Bruce
Gaynes. We assessed whether the peptides have anti-inflammatory effects on
differentiated THP-1s activated with both LPS and ATP. We hypothesized that if Zep
peptides have anti-inflammatory properties like other characterized snake venom
peptides, then activated macrophages treated with Zep peptides would release less IL1β compared to LPS and ATP stimulated macrophages. We followed the same general
protocol that we used for the lidocaine experiments. Here, differentiated THP-1s were
pretreated with either Zep 3 or Zep 4 overnight and at the time of LPS or at the time of
LPS only. The cells were primed with LPS then activated with ATP. The cell supernatant
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was collected, so that the amount of IL-1β released from these cells could be quantified.
If Zep 3 or Zep 4 has an anti-inflammatory effect on differentiated THP-1s, then we
would expect to measure less IL-1β release from peptide treated cells compared to LPS
and ATP only.
Experimental Design: Quantification of IL-1β Release
THP-1s were plated 500,000 cells/well in a 24 well plate. They were
differentiated with 100 ng/mL PMA for 24 hrs. After 24 hrs., the media was changed,
and the cells rested for 36 hrs. The appropriate wells were pretreated with either 12
ug/mL Zep 3 or 50 ug/mL Zep 4 for 16 hrs. Some of the wells were again treated with
either Zep 3 or Zep 4 before 10 ng LPS treatment. After 4 hrs., the differentiated THP1s were treated with 5 mM ATP. After 3.5 hrs, the supernatant was collected to
measure the concentration of IL-1β that was released. A sandwich ELISA was used to
quantify the amount of IL-1β that was secreted (R&D Systems Human IL-1 beta/IL-1F2
DuoSet ELISA). These experiments were repeated more than three times unless
otherwise noted.
Results: Quantification of IL-1β Release
To determine if Zep peptides have anti-inflammatory effects on activated
macrophages, we first measured the amount of IL-1β released from treated
differentiated THP-1s. If Zep peptides have an anti-inflammatory effect on activated
macrophages, then there will be reduction in the amount of IL-1β released from Zep
peptide treated cells.
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With LPS and ATP activation, there was a robust increase in the amount of IL-1β
released compared to no treatment. The differentiated THP-1s treated with Zep 3 or
Zep 4 overnight for 16 hrs. and with a second Zep treatment at the time of LPS
significantly attenuated the release of IL-1β. For cells that were treated with Zep
peptides only at the time of LPS, there was no difference in the amount of IL-1β
released compared to the LPS and ATP only control. These results suggested that Zep
peptide pretreatment does have an anti-inflammatory effect on activated human
macrophage-like cells as seen by a significant decrease in the amount of IL-1β that was
secreted.

Figure 12. Quantification of IL-1β Released from Zep 3 and Zep 4 Treated
Activated Differentiated THP-1s. Differentiated THP-1s were pretreated with Zep 3 or
Zep 4 for 16 hrs. and/or at the time of LPS stimulation. The cells were then stimulated
with both LPS and ATP. A sandwich ELISA was used to quantify the amount of IL-1β
that was released from each condition. This image is representative of at least three
independent experiments.
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Introduction: Quantification of Proinflammatory Cytokine Gene Expression
Since little was known about these Zep peptides, our experimental plan was
exploratory. We followed the same approach we took with lidocaine to better
understand how these peptides attenuated proinflammatory cytokine release. In the
literature, naja naja atra venom and neurotoxin-nna isolated from the venom have been
shown to inhibit NF-κB activation15,16. Based on these earlier studies, it would be
reasonable to hypothesize that Zep peptides may also inhibit NF-κB activation. To test
this hypothesis, we collected the cell lysate from the earlier ELISA experiments for
comparison. The RNA was isolated, cDNA was made, and RT-PCR was performed to
measure changes in proinflammatory cytokine gene expression between Zep peptide
treated activated cells and LPS and ATP only treated cells. Again, there was a 16 hrs.
Zep peptide pretreatment with a second treatment at the time of LPS or the cells were
treated with Zep peptides at the time of LPS only before ATP treatment. Based on the
literature, if Zep peptides attenuated IL-1β release by inhibiting NF-κB, then we would
expect to measure downregulation of proinflammatory cytokine gene expression with
Zep peptide treatment.
Experimental Design: Quantification of Proinflammatory Cytokine Gene
Expression
THP-1s were plated at a density of 500,000 cells/well in a 24 well plate. They
were differentiated with 100 ng/mL of PMA for 24 hrs then allowed to rest for 36 hrs in
fresh RPMI medium. The appropriate wells were pretreated with either 12 ug/mL Zep 3
or 50 ug/mL Zep 4 for 16 hrs. Some of the wells were again treated with either Zep 3 or
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Zep 4 before 10 ng LPS treatment. After 4 hrs., the differentiated THP-1s were treated
with 5 mM ATP. The cell lysate was collected. Then RNA isolation, cDNA conversion,
and RT-PCR were performed on each of the samples. These RT-PCR analyses were
performed on the same treated cells whose supernatant was collected for the previously
described ELISA experiments. This experimental approach allowed for comparisons to
be made between changes in gene expression and the amount of protein released.
Each experimental condition was repeated at least 3 times unless otherwise noted.
Results: Quantification of Proinflammatory Cytokine Gene Expression
To begin to elucidate the anti-inflammatory mechanism of Zep peptides, we
measured the changes in proinflammatory cytokine gene expression. If Zep peptides
reduced IL-1β release from activated macrophages by inhibiting NF-κB or other relevant
transcription factors, then we would expect to measure a decrease in proinflammatory
cytokine gene expression from Zep peptide treated cells.
Similar to the lidocaine results, pretreatment with Zep peptides reduced the
expression of proIL-1β and IL-6. Zep peptide treatment at the time of LPS addition did
not significantly affect gene expression, and the cytokine expression levels were
comparable to the LPS and ATP control. Again, Zep peptide pretreatment had a more
significant effect on proIL-1β expression compared to IL-6. With Zep peptide
pretreatment, proIL-1β expression was comparable to no treatment whereas there was
only a marginal reduction in IL-6 expression. Here, the relative fold change in IL-6
expression from the positive control compared to no treatment was not in the same
range as other experiments. These data corresponded to a higher basal expression of
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proinflammatory cytokines. This variability observed between experiments will be
addressed further in the next chapter. The data suggested that Zep peptides attenuated
IL-1β release from activated macrophages by downregulating proinflammatory cytokine
gene expression.

Figure 13. Zep 3/4 Pretreatment Reduced Gene Expression of proIL-1β and IL-6
from LPS and ATP Activated Macrophages. Differentiated THP-1s were pretreated
with Zep 3/4 for 16 hrs. and/or were treated with Zep 3/4 at the time of LPS treatment.
The macrophage-like cells were treated with LPS for 4 hrs. then ATP for 3.5 hrs. The
cell lysate was collected. The RNA was isolated, cDNA was made, and RT-PCR was
performed for each of the samples. This is a representative image from at least three
independent experiments.
Discussion
A review of the literature showed that snake venom peptides have analgesic and
anti-inflammatory properties, but well-defined mechanisms of action for these peptides
have not been identified15–17,87. In several in vivo models, reduced amounts of IL-1β and
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TNF-α were measured in the serum of animals treated with NNAV or NT before
activation of an inflammatory response15,16. In these same studies, NNAV and NT were
found to inhibit NF-κB activation15,16. It is difficult to draw comparisons between these
prior studies and our work with Zep peptides. Little prior work has been done with these
peptides. Specifically, we are not aware of their regular functions. For example, they
could be enzymes, toxins, or other bioactive molecules which are all commonly found in
snake venom15,87. Furthermore, it would be difficult to identify a cellular target without
knowing more about its structure and function. In the literature, it has been shown
previously that peptides derived from animal venoms inhibited cation channels3. They
bind extracellularly to the channel and insert a side chain into the selectivity filter to
prevent ions from passing through the channel3. Perhaps Zep peptides could also
interact with ion channels to minimize the inflammatory response.
In our experiments, we found that Zep peptide pretreatment before LPS and ATP
activation attenuated IL-1β release, but Zep peptide treatment at the time of LPS had no
effect. Additionally, we found that Zep peptide pretreatment downregulated expression
of proIL-1β and IL-6, but Zep peptide treatment at the time of LPS did not affect gene
expression. The data indicated that Zep peptides were able to reduce an induced
inflammatory response when applied 16 hrs. prior to LPS and ATP. Less IL-1β was
secreted due to reduced gene expression. It is possible that other mechanisms
contributed to Zep peptides’ anti-inflammatory activity. Our studies did not assess the
effect that Zep peptides have on NLRP3 inflammasome formation or identify potential
cellular targets for the peptides. These are both possible future directions that would
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offer a more complete understanding of how Zep peptides diminish inflammatory
activation in macrophage-like cells.
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CHAPTER SIX
OPTIMIZED DIFFERENTIATION OF THP-1s INTO MACROPHAGE-LIKE CELLS
Introduction: Optimized Differentiation of THP-1s into Macrophage-Like Cells
One of the challenges we faced was variability between experiments resulting in
differences in the degree of the effect lidocaine had on activated differentiated THP-1s.
We observed varying results between THP-1s in different cultures and differences as
the cells were in culture for longer periods of time. We noted that based on our qPCR
data the cells became more proinflammatory over time which corresponded to them
being less responsive to activation by LPS and ATP. Additionally, we used PMA to
differentiate the THP-1s into macrophages. PMA activates proinflammatory genes, so it
was important to allow the cells to rest following differentiation. Longer periods of rest
allowed for activation by PMA to subside. Thus, we wanted to identify the time point
when there was a minimum level of background inflammation resulting in a better
response to LPS and ATP activation.
A second factor that was noted was how the morphology of the differentiated
THP-1s varied depending on how long the cells were treated with PMA and how long
they rested. We wanted to identify the ideal length of differentiation and rest before
treating the cells. These conditions should give the most consistently differentiated
THP-1s to reduce variability between experiments. We were looking for the time point
when the cells had the most characteristic morphology of macrophage-like cells. The
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cells should be adherent to the plate with a more triangular, pointed morphology
compared to when they are circular monocytes. Therefore, we aimed to minimize
differences observed in differentiated THP-1s by optimizing the differentiation process
to identify when the cells were most responsive to activation by LPS and ATP.
Experimental Design: Optimized Differentiation of THP-1s into Macrophage-like
Cells
WT THP-1s were seeded at a density of 500,000 cells/well in a 24-well plate. The
cells were differentiated with 100 ng/mL PMA. After 24 or 48 hrs., the media was
replaced with fresh RPMI. The differentiated cells rested for 24 hrs., 48 hrs., 72 hrs.,
and 96 hrs. At each time point, pictures were taken of the differentiated cells to record
how their morphology changed over time. After each of the designated periods of rest,
the cells were treated with 10 ng LPS for 4 hrs. Then the cell lysate was collected.
Samples were collected for no treatment and LPS treatment for each time point of rest.
After all samples were collected, the RNA was isolated, cDNA was made, and RT-PCR
was performed on all the samples. These protocols were executed as described in the
Materials and Methods section.
Results: Optimized Differentiation of THP-1s into Macrophage-like Cells
First, we wanted to understand how the morphology of differentiated THP-1s
changed over time after either 24 hrs. or 48 hrs. of PMA differentiation.
Characterisitcally, when monocytes are differentiated into macrophages, they first have
a more circular shape when they first adhere to the plate and then over time they have a
more triangular and varied morphology. After 48 hrs. of PMA treatment, the THP-1s
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appeared to be more firmly attached to the plate than after onlyl 24 hrs. of PMA
differentiation (Figure 14). Following 24 hrs. of rest for either group, the cells started to
have more varied and triangular shape. Based on morphology alone, the cells that were
differentiated for 48 hrs. before a media change had the most consistent, characteristic
morphology after 72 hrs. of rest. For both differentiation groups, by 96 hrs. of rest most
of the cells were floating after a 4 hr. LPS treatment. Again, based on morphology alone
the cells appeared to have the most characteristic macrophage-like shape after 48 hrs.
of PMA differentiation followed by 72 hrs. of rest.
Next, we measured fold change in gene expression for the proinflammatory
cytokines, IL-1β and IL-6. In general, cells that were differentiated for 48 hrs. were more
responsive to LPS treatment as evidenced by greater fold changes in cytokine
expression compared to no treatment. Furthermore, across conditions, 72 hrs. of rest
resulted in the greatest upregulation of gene expression with LPS treatment. It is worth
noting that between 48 hrs. and 72 hrs. of rest the Ct values for proIL-1β increased by
several cycles after that additional 24 hrs. of rest, meaning that there was less basal
expression of proIL-1β after more rest. This observation was particularly important in our
study because we wanted to find conditions that minimized basal expression of
proinflammatory genes. Overall, the optimal differentiation protocol for THP-1s was 48
hrs. of PMA differentiation then 72 hrs. of rest before treatment. These conditions
produced cells that had charactersitic macrophage morphology and were most
responsive to activation with LPS.
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Figure 14. Morphology of 24 or 48 hrs. PMA Differentiated THP-1s. THP-1s were
differentiated with PMA for either A.) 24 or B.) 48 hrs. Cell images were taken after 24
or 48 hrs. differentiation (labeled day 0), then after 24 hrs, 48 hrs, 72 hrs, or 96 hrs. of
rest.
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Figure 15. Fold Change in Proinflammatory Cytokine Gene Expression of 24 or 48
hrs. PMA Differentiated THP-1s. THP-1s were differentiated with PMA for 24 or 48
hrs. The cells were then allowed to rest for 24 hrs., 48 hrs., 72 hrs., or 96 hrs. They
were activated by LPS for 4 hrs. Then the cell lysate was collected for RNA isolation.
cDNA was made and RT-PCR was performed for each of the samples. A.) 24 hrs. PMA
differentiation fold change in IL-1β gene expression. B.) 24 hrs. PMA differentiation fold
change in IL-6 gene expression. C.) 48 hrs. PMA differentiation fold change in IL-1β
gene expression. D.) 48 hrs. PMA differentiation fold change in IL-6 gene expression.

CHAPTER SEVEN
CONCLUSIONS
Inflammation is commonly associated with the development and progression of
disease. Chronic or unnecessary inflammation can cause tissue damage which
contributes to the pathogenesis of disease. Effective therapeutics that target
inflammatory pathways to minimize excessive inflammation will be valuable in the
treatment of disease1.
Since lidocaine and snake venom peptides have been shown to have antiinflammatory effects on inflammatory models through reduced proinflammatory
cytokine secretion, we hypothesized that lidocaine and Zep peptides also were
able to exert these effects on macrophages by (1) interacting with a cellular target
to decrease intracellular cation concentrations and by (2) downregulating MAPK
and NF-κB signaling pathways to reduce proinflammatory cytokine expression
and release.
The literature has shown that lidocaine and snake venom peptides attenuated
proinflammatory cytokine release from stimulated macrophages, microglial cells, and
other cell types4,5,14–17,6–13. In our study, we sought to determine whether lidocaine and
Zep peptides reduced release of IL-1β from LPS and ATP activated human
macrophage-like cells. Our work has found that pretreatment with lidocaine and Zep
peptides attenuated the release of IL-1β from activated differentiated THP-1s. We then
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aimed to begin to characterize the mechanism of lidocaine and Zep peptides’ antiinflammatory activity. It has been shown in the literature that lidocaine and snake venom
peptides inhibit NF-κB and MAPK activation among other mechanisms4,5,14–17,6–13. We
hypothesized that these anti-inflammatory agents reduced IL-1β release by
downregulating proinflammatory cytokine gene expression. We found that pretreatment
with lidocaine and Zep peptides decreased gene expression of IL-6 and proIL-1β. Our
data suggested that lidocaine and Zep peptides decreased release of inflammatory
mediators in part due to a decrease in proinflammatory cytokine gene expression
(Figure 16). Further work needs to be done to identify cellular targets of these
therapeutics and to further characterize their anti-inflammatory mechanisms of action.
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Figure 16. Model of Lidocaine and Zep peptides’ Anti-inflammatory Activity. LPS
primes TLR4 to upregulate proinflammatory cytokine and NLRP3 gene expression. ATP
is the second signal that activates the P2X7 receptor to initiate NLRP3 inflammasome
formation. Caspase-1 then cleaves proIL-1β into its mature, secreted form that mediates
the inflammatory response. Pretreatment with lidocaine and Zep peptides
downregulated expression of proIL-1β to attenuate IL-1β release. Cellular targets and
other contributing factors to their anti-inflammatory mechanism of action still need to be
identified.
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